Investing.com - Needham lowered its price target on Amphastar Pharmaceuticals (NASDAQ:AMPH) to $30 from $34 while maintaining a Buy rating following the company’s fourth-quarter results. Despite the ...

Net Revenues: $719.9 million for the full year. BAQSIMI Revenue: $185.4 million, up 12% year over year. Primatene Mist Revenue: $108.7 million, up 7% year over year. Iron Sucrose Revenue: $4.4 million ...

Management explicitly guided to lower gross margins in 2026, attributing the pressure to "continued pricing pressure on glucagon, epinephrine, and phytonadione, which are high-margin products," and ...

Amphastar Pharmaceuticals reported its fourth-quarter 2025 earnings, revealing a significant miss in both earnings per share (EPS) and revenue compared to analyst forecasts. The company’s EPS came in ...

Dan Dischner: Thank you, Paul. Good afternoon, everyone, and thank you for joining Amphastar Pharmaceuticals, Inc.'s fourth quarter 2025 earnings call. 2025 was a pivotal year for the company, ...

Dry Powder Inhalers: A Double Win for COPD and Environment By Dennis Thompson HealthDay ReporterTUESDAY, Feb. 24, 2026 (HealthDay News) — Dry powder inhalers might provide a double benefit for people ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...